Marina Kremyanskaya, MD, discusses the effect of CPI-0610 in patients with myelofibrosis.
Marina Kremyanskaya, MD, hematologist/oncologist at Mount Sinai Hospital, discusses the effect of CPI-0610 in patients with myelofibrosis.
In the MANIFEST trial, patients with myelofibrosis who are refractory to or intolerant of ruxolitinib (Jakafi) were treated with the BET inhibitor CPI-0610 in combination with ruxolitinib or CPI-0610 alone. Preclinical data with myelofibrosis models suggest that a combination of BET and JAK inhibitors can result in synergistic reduction of splenomegaly, bone marrow fibrosis, and improvement in anemia, says Kremyanskaya.
It is hopeful that this combination will demonstrate efficacy in the clinical setting, Kremyanskaya concludes.